Navigation Links
Researchers identify new drug target that stimulates

NEW YORK, N.Y., Sept. 6, 2011 -- One of the holy grails in diabetes research is to discover molecules that stimulate beta cell growth and to find drugs that target these molecules. Now, JDRF-funded researchers in collaboration with the pharmaceutical company Hoffmann-La Roche, have done both, discovering not only a protein that regulates beta cell growth, but also a chemical compound that stimulates it. The work appears in the September 7 issue of Cell Metabolism.

The discovery, led by Markus Stoffel, M.D., Ph.D., a professor at the Swiss Federal Institute of Technology in Zurich, represents a significant advance in identifying a new drug target for beta cell regeneration.

The work builds on a discovery made five years ago, when Dr. Stoffel and his team first showed that a once obscure protein, called Tmem27, is localized on the surface membrane of beta cells, the insulin-producing cells that are located within islets in the pancreas. At the time, they found that increased levels of Tmem27 on beta cells were associated with increased islet mass in mice. They also found that if Tmem27 is cleaved, it left the protein completely inactivated.

"We hypothesized that if we could prevent Tmem27 from being cleaved and increase the levels of this protein, we could get more beta cell growth," says Dr. Stoffel, who is also a 2010 recipient of JDRF's Gerold & Kayla Grodsky Basic Research Scientist Award. "This observation gave us the rationale to look for what was inactivating Tmem27."

After screening possible molecules that could snip Tmem27, Dr. Stoffel and his team found the culprit: Bace2, an enzyme protein that, like Tmem27, also resides on the outer surface (known as the plasma membrane) of the beta cell. The researchers confirmed their theory by finding that mice that lacked Bace2 had larger islets and the beta cells in the islets increased in number, a process known as proliferation or regeneration. They also found that these mice were able to clear glucose from the blood more efficiently than control mice with Bace2.

Dr. Stoffel and his team next aimed to inhibit Bace2 in an effort to control and promote the growth of beta cells. To do so, they teamed up with scientists at Hoffmann-LaRoche who developed a chemical compound that could inhibit Bace2. When the scientists gave this compound to mice, they saw that it inhibited Bace2 and stimulated the growth of new beta cells. Importantly, Bace2, and not its close relative Bace1, which is implicated in other diseases, cleaves the Tmem27 protein, suggesting the potential for developing a Bace2 inhibitor as a diabetes-specific therapy.

In addition to identifying a new drug target for promoting beta cell regeneration, Dr. Stoffel's work may also help in developing tests to measure the amount of Tmem27 fragments in the blood a biomarker that could be used as an index of beta cell number.

"This is an exciting and potentially impactful finding," says Patricia Kilian, Ph.D., scientific program director of regeneration research at JDRF. "It's an example of how researchers make an early observation and follow up on it, and then take it to the next level where it has translational potential the potential to be developed into a drug that promotes the growth of beta cells for diabetes."


Contact: Joana Casas
Juvenile Diabetes Research Foundation International

Related biology news :

1. NC State researchers get to root of parasite genome
2. Researchers find animal with ability to survive climate change
3. Researchers find an essential gene for forming ears of corn
4. Researchers note differences between people and animals on calorie restriction
5. Researchers study acoustic communication in deep-sea fish
6. Researchers discover that growing up too fast may mean dying young in honey bees
7. Researchers study how pistachios may improve heart health
8. UI researchers find potentially toxic substance present in Chicago air
9. Researchers develop new self-training gene prediction program for fungi
10. Case Western Reserve University researchers track Chernobyl fallout
11. Childrens National researchers develop novel anti-tumor vaccine
Post Your Comments:
(Date:10/27/2015)... October 27, 2015 Munich, ... Gaze Mapping technology (ASGM) automatically maps data from mobile ... Glasses , so that they can be quantitatively ... Munich, Germany , October 28-29, 2015. ... data from mobile eye tracking videos created with ...
(Date:10/26/2015)... LAS VEGAS , Oct. 26, 2015 ... an innovator in modern authentication and a founding member ... launch of its latest version of the Nok Nok™ ... to use standards-based authentication that supports existing and emerging ... Suite is ideal for organizations deploying customer-facing applications that ...
(Date:10/23/2015)... California , October 23, 2015 ... (SMI) announce a mobile plug and play integration of ... real-world tasks SensoMotoric Instruments (SMI) present ... wearable solutions for eye tracking and physiological data registration. ... SMI Eye Tracking Glasses 2w and physiological ...
Breaking Biology News(10 mins):
(Date:12/1/2015)... ... December 01, 2015 , ... Matthew “Tex” VerMilyea, PhD, HCLD, has joined Texas ... oversee all IVF lab procedures as well as continue his research efforts into the ... miles to Auckland, New Zealand to bring home a High Complexity Clinical Laboratory Director ...
(Date:11/30/2015)... ... ... announced the opening of a new core patient care hub with the opening of ... are part of GSCG’s expansion efforts in Latin America. , Both the Arica and ... from around the world. , The clinics will be headed by Victor Perez, M.D. and ...
(Date:11/30/2015)... HOLLISTON, Mass. , Nov. 30, 2015 /PRNewswire/ ... HART ), a biotechnology company developing bioengineered ... has received written notification from The NASDAQ Stock ... minimum bid price requirements. The letter noted that ... of HART,s common stock having exceeded $1.00 per ...
(Date:11/30/2015)... Human Longevity, Inc. (HLI), the genomics-based, technology-driven ... Genomics, Inc., a leading genome informatics company offering highly ... The San Diego -based company has ... and Co-founder, Ashley Van Zeeland , Ph.D., who is ... of the deal were not disclosed. ...
Breaking Biology Technology: